Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

View original at finance.yahoo.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca currently scores 3 out of 6 on Simply Wall St's valuation checks, meaning the company screens as undervalued on half of the tests used

    60% confidence
  • AstraZeneca is undervalued by 41.1% according to Discounted Cash Flow analysis

    60% confidence
  • The DCF model points to an estimated intrinsic value of £242.86 per share compared with the current share price of £143.02, implying shares trade at a 41.1% discount to fair value

    60% confidence

Data points we hold from this source

AstraZeneca AB · free cash flow projected20.2 USD
AstraZeneca AB · intrinsic value per share242.86 GBP
AstraZeneca AB · stock return 1 month-6.0 percent
AstraZeneca AB · stock return 1 week2.9 percent
AstraZeneca AB · stock return 1 year27.5 percent
AstraZeneca AB · stock return 3 year35.2 percent
AstraZeneca AB · stock return 5 year121.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise Software Races to Govern and Consolidate Around Agentic AI
Enterprise software vendors are repositioning around autonomous AI agents. Salesforce is acquiring Braze, ServiceNow is launching agent governance tools (AI Passport, Super Intelligence Control Tower), SAP is pushing its 'Autonomous Enterprise', and Zeta is launching AthenaOS and its own inference model. Palantir is embedding itself in banking, aviation and sovereign AI infrastructure through partnerships with Customers Bank, Surf Air, Ondas and Armada. Governance, data sovereignty and enforced policy are emerging as preconditions for regulated sectors like finance. Investors such as Norwest see room to disrupt ERP and finance software, and they caution that AI should not be trusted with financial calculations. Consolidation and shareholder disputes (Salesforce/Braze, Tiny/Oso Cloud, ZenaTech/Boardwalktech) show the market reshaping.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback — Source | Via News | ViaNews Market